This paper reports the separation of two chiral antibacterial agents namely, linezolid and tedizolid using a validated high-performance liquid chromatographic method. In the current work, glycopeptide-based chiral column, CHIROBIOTIC® V2 (5-μm particle size, L × I.D. 25 cm × 4.6 mm) was employed with a mobile phase containing methanol and 0.15% aq. trifluoracetic acid (75:25%, v/v) in isocratic elution approach at flow rate of 1 ml min . The separation condition was customized (in terms of resolution values and retention times) was carried out by changing the content of the mobile phase, column temperature, flow rate, and so on. Results showed that the chromatographic separation was achieved within 15 min and average resolution values were 4.6 and 4.8 for tedizolid and linezolid, respectively. The detection limit values were 14.85 and 14.16 ng ml , respectively, for tedizolid enantiomers. Further, validation of separation parameters was performed by considering the international conference on harmonization guidelines, and ultimately, the mechanism of chiral recognition was also established.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/chir.23472 | DOI Listing |
Clin Transl Sci
January 2025
Service de Pharmacie Clinique, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.
Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood-brain barrier, which is the most impermeable. However, inflammation may lead to structural alterations of these barriers, modifying their permeability.
View Article and Find Full Text PDFAntibiotics (Basel)
December 2024
Department of Infectious Diseases, St. Luke's International Hospital, Tokyo 104-8560, Japan.
: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited. This study aimed to evaluate the safety of long-term TZD use in Japanese patients, including those with HM.
View Article and Find Full Text PDFJ Infect Chemother
December 2024
Department of Infection Prevention and Control, Aichi Medical University Hospital, Nagakute, Aichi, Japan; Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan. Electronic address:
Thrombocytopenia derived from tedizolid (TZD) has been reported but less frequently than that from linezolid. Only a few reports have investigated the relationship between the efficacy and safety of TZD administration. This study aimed to measure TZD concentration and investigate the relationship between efficacy and safety.
View Article and Find Full Text PDFJ Glob Antimicrob Resist
November 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin, PR China.
Objective: The objective of this study was to investigate the cumulative fraction of response of various dosage regimens of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults.
Methods: Monte Carlo simulations were performed using previously published pharmacokinetic parameters and pharmacodynamic data to evaluate the efficacy of the simulated dosage strategies in terms of area under the concentration-time curve/minimum inhibitory concentration targets of tedizolid.
Results: According to the results of the Monte Carlo simulations, currently approved dosage regimens of tedizolid phosphate were effective in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-susceptible S.
Antibiotics (Basel)
September 2024
College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!